NCT01084655View on ClinicalTrials.gov

Study of TAK-700 in Combination With Docetaxel and Prednisone in Men With Metastatic Castration-Resistant Prostate Cancer

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

38

Participants

Timeline

Start Date

July 31, 2010

Primary Completion Date

January 31, 2013

Study Completion Date

March 31, 2016

Conditions
Prostate Cancer
Interventions
DRUG

TAK-700

TAK-700 with docetaxel and prednisone on a continuous schedule.

DRUG

Docetaxel

TAK-700 with docetaxel and prednisone on a continuous schedule.

DRUG

Prednisone

TAK-700 with docetaxel and prednisone on a continuous schedule.

Trial Locations (1)

99508

Alaska Clinical Research Center, LLC, Anchorage

Sponsors
All Listed Sponsors
lead

Millennium Pharmaceuticals, Inc.

INDUSTRY